NYU School of Medicine Clinical Trails>>
 Columbia University Medical Center • Taub Institute
Clinical Trials
REFLECT 3: Effects of Rosiglitazone-XR on
Mild-to-Moderate Alzheimer’s Disease
We are seeking English and Spanish-speaking men and
women, ages 50-90, to participate in a Phase III study to
determine the effectiveness of Rosiglitazone-XR on
cognitive function and clinical response in patients diagnosed
with Alzheimer’s disease. Participants must have
been on standard cholinesterase therapy for 6 months
and have a family member or caregiver who can attend
appointments during the research study. For more information,
please contact Sarah Downs at 212-305-2077.
Study of DHA Omega-3 Fatty Acid in
Mild-to-Moderate Alzheimer’s Disease
Scientists want to learn if one omega-3 fatty acid, called
DHA, can slow the progression of Alzheimer’s disease.
We are seeking men and women age 55 or older with
mild-to-moderate Alzheimer’s disease who are fluent in
English or Spanish. Participants are allowed to remain on
their regular AD medications and must have a family member
or caregiver to accompany them to all study visits.
For more information, please contact Ruth Tejeda at 212-305-7661.
Safety and Efficacy of AC-3933 in
Mild-to-Moderate Alzheimer’s Disease
We are seeking men and women age 55 or older with
mild-to-moderate Alzheimer’s disease to participate in a
Phase II study using the investigational drug,AC-3933.
Each participant must have a family member or caregiver
who can attend appointments during the research study.
If interested, please contact Evelyn Dominguez at 212-305-2371.
Study to Improve Sleep in Alzheimer’s Disease Patients
We are seeking men and women, age 55 and older, with
mild-to-moderate Alzheimer’s disease to participate in a
8-week study to determine the effectiveness, safety, and
tolerability of Rozerem in treating sleep disturbances.All
participants must have a family member or caregiver to
accompany them to study visits. For more information, please
contact Ruth Tejeda at 212-305-7661.
Valproate in Dementia (VALID) Study
We are seeking English and Spanish-speaking men and
women between 55 and 90 years of age to participate in
a study to determine whether Valproate (a standard anticonvulsant
medication) is effective in delaying or preventing
the development of difficult behaviors such as
agitation or psychosis in people with Alzheimer’s disease
(AD). This study will also determine whether Valproate
slows the progression of AD. Participants must have a
diagnosis of AD and have not experienced agitation or
psychosis since the onset of the AD. If interested, please
contact Ruth Tejeda at 212-305-7661.
Antipsychotic Medication Treatment of Psychosis and
Behavioral Dyscontrol in Alzheimer’s Disease Study
This research study, funded by the National Institute of
Aging, uses risperidone (an FDA-approved antipsychotic
medication) to treat people with Alzheimer’s disease who
suffer from hallucinations, delusions, agitation, and/or
aggression.Treatment continues over a period of 48 weeks.
Each eligible participant must have a family member or
caregiver who can assist with adherence to treatment and
provide information during the research study. For further
information, please contact Michelle Motta at 212-543-6132.
Antidepressant Treatment Studies for Combined
Depression and Memory Complaints
We are currently conducting medication treatment studies
for individuals (age 50+) experiencing both depression
and mild memory and/or concentration difficulties.
The studies offer both neuropsychological testing for
memory and psychiatric evaluation of mood prior to and
during the period of treatment. Treatment in our clinic is
provided for eligible individuals at no cost for at least 6
months. For further information, please contact Oliver Harper at
212-543-5067.
NEUROIMAGING STUDIES
Alzheimer’s Disease Neuroimaging Study
We are seeking English and Spanish-speaking men and
women, age 55 to 90, who have normal memory, or mild
memory problems, or early Alzheimer’s disease, to participate
in a study to determine whether imaging of the
brain with PET or MRI scans every 6 months can help
predict and monitor the onset and progression of
Alzheimer’s disease. In addition to the neuroimaging, the
study will collect blood and, for some participants, cerebral
spinal fluid to determine if biomarkers can predict and
monitor the disease. No medication will be prescribed.
To participate or get more information about the study, please contact
Nick Adams at 212-342-0522 or Rachel Scherer at 212-305-1987.
Amyloid and Glucose Brain Imaging Research Study
for People With and Without Memory Problems
This study uses imaging procedures to understand brain
changes that are related to Alzheimer’s disease.
Participants receive a Positron Emission Tomography
(PET) scan that uses a radioactive marker that is taken up
by abnormal deposits (a.k.a. amyloid deposits), which
may be related to Alzheimer’s disease. A PET glucose
scan and an MRI scan, which are standard clinical procedures, are also done in this research study. These procedures
are performed once at an initial visit and then
again one year later. Participants are reimbursed $100 for
a PET scan day and $50 for an MRI scan. For further
information, please contact Katrina Cuasay at 212-543-5025.
Brain Imaging Study of Smell Function in Healthy
Individuals and Patients with Memory Complaints
This study uses brain-imaging procedures to understand
how aging and Alzheimer’s disease affect smell function.
Healthy individuals and patients with memory complaints
or with Alzheimer’s disease receive a Functional
Magnetic Resonance Imaging (fMRI) scan while
smelling common odors (e.g., coffee). Similar to standard
MRI, which looks at brain structures, fMRI uses magnetic
fields and radio waves to look at how the brain is
functioning. This study will help us to understand the
changes that occur in brain activity with age and disease
progression. For further information, please contact Matt Tabert,
PhD, at 212-543-5046.
OTHER STUDIES
Genetic Linkage Study
We are seeking Caribbean Hispanic families for a study
to identify genes that may increase the risk for
Alzheimer’s disease (AD). If you have at least two living family
members diagnosed with AD, please call Vincent Santana at
1-800-243-5828 or Jennifer Williamson at 212-305-4655.
ADDITIONAL INFORMATION
Brain Donation Program “Give the Gift of Knowledge”
Brain donation allows valuable information to be
obtained regarding normal aging and diseases that affect
memory. This information may be useful towards the
goal of developing more effective treatment strategies.
If you or a family member wish to learn more about this program,
please call Arlene Lawton, RN, at 212-305-9086.
Lucy G. Moses Center for
Memory and Behavioral Disorders
Changes in memory and thinking abilities can occur
from a variety of conditions, not just Alzheimer’s disease.
Taub Institute specialists offer a thorough multidisciplinary
evaluation of memory and thinking difficulties at
two locations:
The Neurological Institute
710 West 168th Street
New York, NY 10032
Columbia Presbyterian Eastside
1
6 East 60th Street
New York, NY 10022
For Appointments call: 212-305-6939.
NYU School of Medicine Clinical Trails>>
 Previous | Next 
|
